ALEC Alector, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1653087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY151.1%
TTM net income YoY138.4%
TTM EPS YoY134.0%
Revenue 3-yr CAGR21.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin20.2%
Net margin23.9%
FCF margin-86.5%
EBITDA margin22.6%
Returns
ROE47.5%
ROA16.5%
ROIC (approx.)217.2%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets29.7%
Debt / equity0.00x
Current ratio4.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.62x
Accruals ratio76.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $21.05M | $100.56M |
| R&D expense | $123.06M | $185.94M |
| SG&A expense | $53.99M | $59.62M |
| Operating income | -$156.01M | -$145.00M |
| Pretax income | -$142.76M | -$118.92M |
| Income tax | $168,000 | $128,000 |
| Net income | -$142.93M | -$119.05M |
| EBITDA | -$150.29M | -$139.59M |
| EPS (basic) | -1.39 | -1.23 |
| EPS (diluted) | -1.39 | -1.23 |
| Weighted avg. shares (diluted) | 103.00M | 96.59M |
| Balance sheet | ||
| Cash & equivalents | $65.80M | $34.87M |
| Short-term investments | $190.22M | $380.38M |
| Current assets | $266.45M | $424.82M |
| PP&E, net | $10.84M | $17.14M |
| Total assets | $293.24M | $468.30M |
| Current liabilities | $69.50M | $125.06M |
| Short-term debt | $366,000 | $0 |
| Long-term debt | $9.32M | $9.39M |
| Total debt | $9.69M | $9.39M |
| Total liabilities | $262.59M | $341.50M |
| Shareholders' equity | $30.65M | $126.80M |
| Net debt | -$56.11M | -$25.48M |
| Shares outstanding | 110.36M | 99.09M |
| Cash flow statement | ||
| Operating cash flow | -$184.03M | -$229.91M |
| Capital expenditure | $41,000 | $1.25M |
| Free cash flow | -$184.07M | -$231.16M |
| Investing cash flow | $196.60M | $107.13M |
| Financing cash flow | $20.21M | $81.54M |
| Depreciation & amortization | $5.72M | $5.41M |
| Stock-based compensation | $26.66M | $39.46M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.